LMY-920 is under clinical development by Luminary Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LMY-920’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LMY-920 overview

LMY-920 is under development for the treatment of mantle cell lymphoma, scleroderma, relapsed and refractory multiple myeloma, non-Hodgkin lymphoma, systemic lupus erythematosus and acute lymphoblastic leukemia. The therapeutic candidate comprises of autologous T-cells that are genetically modified by transposon transduction to express chimeric antigen receptor (CAR) that targets B cell activating factor receptor (BAFF). It is being developed based on the Tcbuster technology.

It was also under development for Sjogren’s syndrome.

Luminary Therapeutics overview

Luminary Therapeutics is a cell therapy development company that discovers non-viral autologous treatments for cancer and autoimmune diseases. The company offers therapeutic solutions like Baff CAR-T immunotherapies, universal receptors that cells can multitask, non-viral allogeneic platform. It is investigating LMY-920, a non-viral CAR-T cell therapy targeting B-cell malignancies and autoimmune disorders, and LMY-232 to treat solid tumors and autoimmune diseases. Luminary Therapeutics also provides various programs. The company seeks to work in partnership with key antibody companies to discover new chimeric antigen receptors (CAR’s). Luminary Therapeutics is headquartered in Minneapolis, Minnesota, the US.

For a complete picture of LMY-920’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.